Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Vaccine

Volumn 32, Issue 39, 2014, Pages 4925-4931

  Gaggar, Anuj ^a   Coeshott, Claire ^b   Apelian, David ^b   Rodell, Timothy ^b   Armstrong, Brian R ^c   Shen, Gong ^a   Subramanian, G Mani ^a   McHutchison, John G ^a  

^a GILEAD SCIENCES   (United States)

^b GlobeImmune Inc   (United States)

^c QST Consultations Ltd   (United States)

Author keywords

GS 4774; HBV; Healthy subjects; Vaccine

Indexed keywords

GAMMA INTERFERON; GS 4774; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; HEPATITIS B ANTIBODY; RECOMBINANT VACCINE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE REACTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE; BLOOD; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; NORMAL HUMAN; SACCHAROMYCES CEREVISIAE; YOUNG ADULT;

ADULT; AGED; FEMALE; HEALTHY VOLUNTEERS; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MALE; MIDDLE AGED; SACCHAROMYCES CEREVISIAE; T-LYMPHOCYTES; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84906090057     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.027     Document Type: Article

References (21)

1. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13:29-60.
2. Webster G.J., Reignat S., Maini M.K., Whalley S.A., Ogg G.S., King A., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000, 32:1117-1124.
3. Bertoletti A., Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 2006, 87:1439-1449.
4. Revill P., Yuan Z. New insights into how HBV manipulates the innate immune response to establish acute and persistent infection. Antivir Ther 2013, 18:1-15.
5. Tujios S.R., Lee W.M. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013, 29:250-256.
6. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7:625-629.
7. Guo Z., Kemmler C.B., Derrick L.M., Mann D.L., Lu Y., Bellgrau D., et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, and core antigens generate antigen specific T cell responses and tumor protection in mice. Poster 375. The Liver Meeting 2012. 63rd annual meeting of the American Association for the Study of Liver Diseases. November 9-13 2012.
8. Kemmer C.B., Mann D.L., King T.H., Guo Z., Bellgrau D., Subramanian M., et al. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, and core antigens generate antigen specific T cell responses in clinical immune cell samples from healthy volunteers. Poster 372. The Liver Meeting 2012. 63rd annual meeting of the American Association for the Study of Liver Diseases. November 9-13 2012.
9. Currier J.R., Kuta E.G., Turk E., Earhart L.B., Loomis-Price L., Janetzki S., et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260:157-172.
10. Schaffer T., Müller S., Flogerzi B., Seibold-Schmid B., Schoepfer A.M., Seibold F. Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm Bowel Dis 2007, 13:1339-1346.
11. Konrad A., Rütten C., Flogerzi B., Styner M., Göke B., Seibold F. Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. Inflamm Bowel Dis 2004, 10:97-105.
12. Bryant P., Ploegh H. Class II MHC peptide loading by the professionals. Curr Opin Immunol 2004, 16:96-102.
13. Halperin S.A., Van Nest G., Smith B., Abtahi S., Whiley H., Eiden J.J. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003, 21:2461-2467.
14. Halperin S.A., Dobson S., McNeil S., Langley J.M., Smith B., McCall-Sani R., et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006, 24:20-26.
15. Beran J., Hobzova L., Wertzova V., Kuriyakose S., Leyssen M., Surquin M., et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccine 2010, 6:578-584.
16. Jacobson I.M., McHutchison J.G., Boyer T.D., Schiff E.R., Everson G.T., Pockros P.J., et al. 2006 GI-5005 therapeutic vaccine plus peg-IFN/ribavirin significantly improves virologic response and ALT normalization at end-of-treatment and improves SVR24 compared to peg-IFN/ribavirin in genotype-1 chronic HCV patients. J Hepatol 2010, 52:S465-S466.
17. McHutchison J.G., Goodman Z.D., Everson G.T., Jacobson I.M., Boyer T.D., Schiff E.R., et al. GI-5005 therapeutic vaccine plus peg-IFN/ribavirin improves biopsy necro-inflammatory scores and ALT normalization at 48 weeks versus peg-IFN/ribavirin in genotype 1 chronic HCV patients. Poster 277. The International Liver CongressTM 2010. 45th Annual meeting of the European Association for the Study of the Liver. April 14-18 2010.
18. Habersetzer F., Baumert T.F., Stoll-Keller F.G.I-5005 GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009, 11:456-462.
19. Vandepapelière P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25:8585-8597.
20. Hoa P.T., Huy N.T., Thu le T., Nga C.N., Nakao K., Eguchi K., et al. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 2009, 53:5134-5140.
21. Xu D-Z., Zhao K., Guo L-M., Chen X-Y., Wang H-F., Zhang J-M., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 2008, 3:e2565.